{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000641","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.831690+00:00","generated_at":"2026-05-27T02:47:55.900482+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aprea Therapeutics updates patent portfolio for ATR and WEE1 inhibitor programs","bullets":["ATR inhibitor program: 4 granted US patents, 1 pending US application, 1 provisional; 19 granted non-US patents, 16 pending non-US applications.","Granted patents expire 2035-2037; pending applications may extend exclusivity to 2044.","Lead ATR inhibitor ATRN-119 in Phase 1 ABOYA-119 trial for solid tumors with DDR mutations.","WEE1 inhibitor program: 1 pending US application, 12 pending non-US applications; if granted, expire 2043.","Lead WEE1 inhibitor APR-1051 in Phase 1 ACESOT-1051 trial for advanced/metastatic solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000641","json":"https://secwatch.observer/filing/0001558370-25-000641.json","markdown":"https://secwatch.observer/filing/0001558370-25-000641.md","text":"https://secwatch.observer/filing/0001558370-25-000641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025000641/0001558370-25-000641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025000641/apre-20250205x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:47:55.900482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}